Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued
Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy ...
Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Earnings Call Transcript
Q3 2025 Earnings Call Transcript January 30, 2025 Christopher O’Reilly: [Foreign Language] Let me start, I’d like to remind ...
Takeda Pharmaceutical Co.: Hold Rating Amid Mixed Q3 Results, Upward Guidance Revision, and Strategic Moves
Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...
Takeda signals 2025 growth with raised guidance, JPY 100B buyback, and new leadership transition
Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Management View Christophe Weber, CEO, announced his retirement ...
Takeda Pharmaceutical: Strong Financials, Strategic Leadership Change, and Robust Pipeline Justify Buy Rating
Koichi Mamegano, an analyst from Bank of America Securities, maintained the Buy rating on Takeda Pharmaceutical Co (TKPHF – Research Report).
Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance
Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...
Bloomberg L.P.19h
Takeda Pharmaceutical Co Ltd
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
Indiatimes23h
Asahi Ind Glass - Asahi India Glass Share Price
Company has reported net profit after tax of Rs 93.06 Crore in latest quarter.The company’s top management includes Mr.Sanjay Labroo, Mr.Masao Fukami, Mr.Gurvirendra Singh Talwar, Mr.Masahiro Takeda, ...